Tag - InflaRx

InflaRx (NASDAQ:IFRX) reported that IFX-1 missed its primary endpoint in a Phase 2b trial in hidradenitis suppurativa (HS) patients. HS a chronic inflammatory skin disease that causes abscesses and scarring. IFX-1 is a...